(Q65351997)

English

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

short name

CIMPASI-2 (English)

0 references

title

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis (English)

0 references

0 references

0 references

0 references

0 references

United States of America